Mosseri Marlio Charles
SEC CIK 1806384 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | 10% | 3.19M | $7.92M | — | 27 | 2023-06-15 | 2026-06-30 |
Most active insiders at NVCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mosseri Marlio Charles | 10% | $1.87M | — |
| 2 | BENTSUR RON | COB, CEO, Dir, 10% | $278.6K | — |
| 3 | Sanchez Juan | Dir | $75.3K | — |
| 4 | Kaplan Matthew L. | Dir | $64.2K | — |
| 5 | Poradosu Enrique | Chief Science, Business Off | — | — |
| 6 | Carson Michael J. | VP, Fin | — | — |
| 7 | Shemesh Shay | Chief Dev, Ops. Off | — | — |
| 8 | Hoberman Kenneth | Dir | — | — |
| 9 | Oliviero James F III | Dir | — | — |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-07-01 13:41 | 2026-06-30 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $18.32 | +50.0K | 3.19M | +2% | +$916.0K |
| MI | 2025-10-29 | 2025-10-23+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $6.18 | +154.8K | 3.06M | +5% | +$957.1K |
| I | 2025-06-24 | 2025-06-20 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $7.99 | +5,603 | 2.98M | +0.2% | +$44.8K |
| MI | 2025-06-20 | 2025-06-17+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $8.06 | +33.4K | 2.95M | +1% | +$269.5K |
| I | 2025-05-13 | 2025-05-12 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $8.11 | +21.2K | 2.94M | +0.7% | +$171.7K |
| MAI | 2025-05-12 | 2025-05-08+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $8.94 | +27.7K | 2.91M | +1.0% | +$247.3K |
| MI | 2025-05-09 | 2025-05-06+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $8.60 | +27.4K | 2.90M | +1.0% | +$235.6K |
| I | 2025-02-11 | 2025-02-07 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $5.00 | +240.0K | 2.88M | +9% | +$1.20M |
| MA | 2024-12-16 | 2024-12-12+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $4.66 | +49.1K | 2.63M | +2% | +$228.9K |
| 2024-12-16 | 2024-12-13 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $4.70 | +17.0K | 2.61M | +0.7% | +$79.9K | |
| 2023-08-01 | 2023-07-31 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $13.88 | +860 | 2.60M | +0.0% | +$11.9K | |
| 2023-07-31 | 2023-07-28 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $13.91 | +2,584 | 2.59M | +0.1% | +$35.9K | |
| 2023-07-28 | 2023-07-27 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $13.98 | +1,556 | 2.59M | +0.1% | +$21.8K | |
| 2023-07-27 | 2023-07-26 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $13.97 | +10.0K | 2.59M | +0.4% | +$139.7K | |
| M | 2023-07-24 | 2023-07-20+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $14.47 | +8,238 | 2.58M | +0.3% | +$119.2K |
| 2023-07-20 | 2023-07-19 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $14.84 | +8,000 | 2.57M | +0.3% | +$118.7K | |
| 2023-07-19 | 2023-07-18 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $14.84 | +9,149 | 2.56M | +0.4% | +$135.8K | |
| 2023-07-13 | 2023-07-12 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $15.09 | +3,285 | 2.55M | +0.1% | +$49.6K | |
| 2023-07-12 | 2023-07-11 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $15.36 | +10.0K | 2.55M | +0.4% | +$153.6K | |
| 2023-07-10 | 2023-07-07 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $15.19 | +8,948 | 2.54M | +0.4% | +$135.9K | |
| 2023-07-07 | 2023-07-06 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $15.01 | +3,179 | 2.53M | +0.1% | +$47.7K | |
| 2023-07-06 | 2023-07-05 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $15.52 | +1,176 | 2.53M | +0.0% | +$18.3K | |
| 2023-06-27 | 2023-06-26 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $16.46 | +16.8K | 2.53M | +0.7% | +$275.9K | |
| 2023-06-26 | 2023-06-23 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $17.43 | +73.2K | 2.51M | +3% | +$1.28M | |
| M | 2023-06-23 | 2023-06-21+ | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $17.72 | +13.1K | 2.44M | +0.5% | +$232.0K |
| 2023-06-20 | 2023-06-16 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $17.75 | +12.7K | 2.42M | +0.5% | +$225.4K | |
| M | 2023-06-16 | 2023-06-15 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $17.71 | +32.1K | 2.41M | +1% | +$568.8K |
Purchase Sale Sale after option exercise All abbreviations